Brain signal IDs responders to fast-acting antidepressantAugust 06, 2012
Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers.
The signal is among the latest of several such markers, including factors detectable in blood, genetic markers, and a sleep-specific brain wave, recently uncovered by the NIH team and grantee collaborators. They illuminate the workings of the agent, called ketamine, and may hold promise for more personalized treatment.
"These clues help focus the search for the molecular targets of a future generation of medications that will lift depression within hours instead of weeks," explained Carlos Zarate, M.D., of the NIH's National Institute of Mental Health (NIMH). "The more precisely we understand how this mechanism works, the more narrowly treatment can be targeted to achieve rapid antidepressant effects and avoid undesirable side effects."
Zarate, Brian Cornwell, Ph.D., and NIMH colleagues report on their brain imaging study online in the journal Biological Psychiatry.
Previous research had shown that ketamine can lift symptoms of depression within hours in many patients. But side effects hamper its use as a first-line medication. So researchers are studying its mechanism of action in hopes of developing a safer agent that works similarly.
Ketamine works through a different brain chemical system than conventional antidepressants. It initially blocks a protein on brain neurons, called the NMDA receptor, to which the chemical messenger glutamate binds. However, it is not known if the drug's rapid antidepressant effects are a direct result of this blockage or of downstream effects triggered by the blockage, as suggested by animal studies.
To tease apart ketamine's workings, the NIMH team imaged depressed patients' brain electrical activity with magnetoencephalography (MEG). They monitored spontaneous activity while subjects were at rest, and activity evoked by gentle stimulation of a finger, before and 6.5 hours after an infusion of ketamine.
It was known that by blocking NMDA receptors, ketamine causes an increase in spontaneous electrical signals, or waves, in a particular frequency range in the brain's cortex, or outer mantle. Hours after ketamine administration--in the timeframe in which ketamine relieves depression - spontaneous electrical activity in people at rest was the same whether or not the drug lifted their depression.
Electrical activity evoked by stimulating a finger, however, was different in the two groups. MEG imaging made it possible to monitor excitability of the somatosensory cortex, the part of the cortex that registers sensory stimulation. Those who responded to ketamine showed an increased response to the finger stimulation, a greater excitability of the neurons in this part of the cortex.
Such a change in excitability is likely to result, not from the immediate effects of blocking the receptor, but from other processes downstream, in the cascade of effects set in motion by NMDA blockade, say the researchers. Evidence points to changes in another type of glutamate receptor, the AMPA receptor, raising questions about whether the blocking of NMDA receptors is even necessary for ketamine's antidepressant effect. If NMDA blockade is just a trigger, then targeting AMPA receptors may prove a more direct way to effect a lifting of depression.
A separate study of ketamine biomarkers by the NIMH group adds to evidence that the drug may work, in part, by strengthening neural connections. Thirty treatment resistant depressed patients who received ketamine showed increased sleep-specific slow brainwave activity (SWA) - a marker of such strengthened synapses and of increased synchronization of networks in the cortex. They also had higher blood levels of a key neural growth chemical, brain-derived neurotrophic factor (BDNF), previously linked, in animal studies, to ketamine's action. Intriguingly, the boosts in BDNF were proportional to those in SWA only among 13 participants whose depressions significantly lifted - suggesting a potential marker of successful treatment.
"Linked SWA and BDNF may represent correlates of mood improvement following ketamine treatment," said Zarate. "These may be part of the mechanism underlying the rapid antidepressant effects and prove useful in testing potential new therapies that target the glutamate system."
The increases in SWA, detected via electroencephalography (EEG), were also reflected in increased slope and amplitude of individual brainwaves - additional indicators of neural health and adaptability.
Prior to discovery of ketamine's antidepressant effects, the only fast-acting antidepressant therapies were sleep deprivation and electroconvulsive therapy (ECT), both of which are also thought to work, at least in part, by stimulating BDNF.
There is also new evidence that people with one of two common versions of the gene that codes for BDNF respond better to ketamine - and clues about why. The versions are created by a site in the human BDNF gene where the genetic code differs slightly across individuals. Each person inherits two copies of the gene, one from each parent. So people can inherit one or two copies of each version.
In June, NIMH-funded researchers reported that ketamine's ability to spur the growth of neural connections and trigger antidepressant-like behavioral responses was impaired in mice genetically engineered to express two copies of a risk version of the human BDNF gene that is carried by about 30 percent of the population. NIMH grantees George Aghajanian M.D., and Ronald Duman, Ph.D., of Yale University, New Haven, Conn., also discovered atrophy in extensions of neurons and dampened electrical activity in key cells at the front of the brain, with the risk version.
The mouse results suggested that the same site of variability in the BDNF gene might similarly influence patients' responses to ketamine. In July, Zarate and NIMH colleagues reported that in 62 depressed patients, this variability in the BDNF gene accounted for 28 percent of difference in patients' responsiveness to the medication. As expected, the antidepressant effect was strongest in patients with two copies of the other, protective version, which is carried by about 60 percent of the population.
These results strengthen the case for BDNF's pivotal role in mediating antidepressant effects produced via the glutamate system. They also suggest that it might be possible to improve ketamine's antidepressant effect in risk version carriers by first giving them treatments known to enhance BDNF, such as exercise, transcranial magnetic stimulation, ECT, or conventional antidepressants.
In another recent study by the NIMH team and NIH collaborators, by-products of the chemical breakdown of ketamine, detectable in blood, helped to sort out responders from non-responders, as well as diagnosis and symptoms. This first study of its kind pinpointed correlates of such downstream ketamine metabolites in 45 treatment resistant depressed unipolar and 22 depressed bipolar patients.
Blood levels of one metabolite were higher among bipolar non-responders, indicating that these patients might require a lower dose of the drug for optimal efficacy. Levels of three related metabolites were higher in bipolar patients, with only one, of a different type, elevated in patients with major depression. Higher levels of three metabolites of the former type were also associated with lower scores on measures of psychotic and other side effects, following ketamine treatment. The identification of these downstream metabolites opens the door to possibly developing them into newer treatments that are better tolerated than ketamine.
Ketamine also recently produced the fastest, strongest and longest-lasting anti-suicidal intervention ever demonstrated in a controlled trial, according to Zarate and colleagues. In a replication of an earlier study, the researchers confirmed that ketamine not only lifts depression, but also reduces suicidal thoughts in bipolar patients. The effects were detectable as soon as 40 minutes after a single infusion in 15 treatment resistant patients taking mood stabilizers, and remained significant for at least a few days. Three fourths of the patients responded to ketamine, with none responding to a placebo. The results add reduced suicidal thinking to the list of potential therapeutic benefits of targeting the brain's glutamate system.
While the research on biological markers and mechanisms holds hope for development of more practical medications in the long term, questions remain about whether there might be a limited role for ketamine itself in the short term.
In a recent assessment of the state of the science, Zarate and American and European colleagues propose that intravenous ketamine may prove useful for acutely suicidal patients who receive treatment in hospital emergency rooms. It may also offer an alternative to ECT, long considered the treatment of last resort for treatment resistant depression, but fraught with concerns about cognitive side effects.
However, the researchers recommend against the use of ketamine outside of a hospital setting, citing potential cardiovascular and other risks. They note that anesthesiologists participate in the trials at NIMH and Mount Sinai School of Medicine, New York City which also require a 24-hour inpatient stay following drug infusion.
Among about 163 patients who have been studied to date, the drug has been well tolerated and seems a reasonable treatment option for most treatment resistant depressed patients, say the researchers. Studies are under way using nasally administered ketamine and other strategies to determine how the rapid antidepressant affect might best be sustained.
"We are investigating ketamine in multiple ways - studying genes, gene expression, synapses, cells, circuits, and symptoms with neuroimaging, genetics, electrophysiological measures and other techniques," explained Zarate. "These studies hold hope for predicting the likelihood of response and for gaining insights into mechanisms of action."
Synaptic Potentiation Is Critical for Rapid Antidepressant Response to Ketamine in Treatment-Resistant Major Depression. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr. Biol Psychiatry. 2012 Apr 20. [Epub ahead of print] PMID: 22521148
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA. Int J Neuropsychopharmacol. 2012 Jun 7:1-11. [Epub ahead of print] PMID: 22676966
Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, Moaddel R, Wainer IW. Biol Psychiatry. 2012 Apr 18. [Epub ahead of print] PMID: 22516044
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA. Biol Psychiatry. 2012 Jun 1;71(11):939-46. Epub 2012 Jan 31.PMID: 22297150
Ketamine for Depression: Where Do We Go from Here? Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Biol Psychiatry. 2012 Jun 15. [Epub ahead of print] PMID: 22705040
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, Kelmendi B, Simen A, McMahon FJ, Sanacora G, Zarate C Jr. Biol Psychiatry. 2012 Jul 5. [Epub ahead of print] No abstract available. PMID:22771240
NIH/National Institute of Mental Health
Related Depression Articles:
A thought is a thought. It does not reflect reality.
Depression is associated with sadness, fatigue and a lack of motivation.
Patients with depression can be categorized into four unique subtypes defined by distinct patterns of abnormal connectivity in the brain, according to new research from Weill Cornell Medicine.
Studies presented at this year's International Early Psychosis Association meeting in Milan, Italy, (Oct.
Having both parents and grandparents with major depressive disorder was associated with higher risk of MDD for grandchildren, which could help identify those who may benefit from early intervention, according to a study published online by JAMA Psychiatry.
Postpartum depression -- a household term since actress Brooke Shields went public in 2005 about her struggle with it -- is indeed serious.
Tropical Depression 1E or TD1E didn't get far from the time it was born to the time it weakened to a remnant low pressure area along the southwestern coast of Mexico.
MIT researchers have found that brain scans may identify children who are vulnerable to depression, before symptoms appear.
Participants in a national survey read a scenario describing someone who had depressed symptoms.
How can you tell if someone is depressed? The Diagnostic and Statistical Manual of Mental Disorders (DSM) -- the 'bible' of psychiatry -- diagnoses depression when patients tick off a certain number of symptoms on the DSM checklist.
Related Depression Reading:
The Depression Cure: The 6-Step Program to Beat Depression without Drugs
by Stephen S. Ilardi (Author)
In the past decade, depression rates have skyrocketed, and one in four Americans will suffer from major depression at some point in their lives. Where have we gone wrong? Dr. Stephen Ilardi sheds light on our current predicament and reminds us that our bodies were never designed for the sleep-deprived, poorly nourished, frenzied pace of twenty-first century life.
Inspired by the extraordinary resilience of aboriginal groups like the Kaluli of Papua New Guinea, Dr. Ilardi prescribes an easy-to-follow, clinically proven program that harks back to what our bodies were originally made for and... View Details
The Upward Spiral: Using Neuroscience to Reverse the Course of Depression, One Small Change at a Time
by Alex Korb PhD (Author), Daniel J. Siegel MD (Foreword)
Depression can feel like a downward spiral, pulling you into a vortex of sadness, fatigue, and apathy. In The Upward Spiral, neuroscientist Alex Korb demystifies the intricate brain processes that cause depression and offers a practical and effective approach to getting better. Based on the latest research in neuroscience, this book provides dozens of straightforward tips you can do every day to rewire your brain and create an upward spiral towards a happier, healthier life.
Whether you suffer from depression or just want a better understanding of the brain, this book... View Details
Depression & Other Magic Tricks
by Sabrina Benaim (Author)
Depression & Other Magic Tricks is the debut book by Sabrina Benaim, one of the most-viewed performance poets of all time, whose poem "Explaining My Depression to My Mother" has become a cultural phenomenon with over 50,000,000 views. Depression & Other Magic Tricks explores themes of mental health, love, and family. It is a documentation of struggle and triumph, a celebration of daily life and of living. Andrea Gibson, author of Pansy, writes "I read this book on a day I couldn't get out of bed and it made me feel like I had a friend in the world...Simply put, this book disappears... View Details
The Mindful Way Through Depression: Freeing Yourself from Chronic Unhappiness (Book & CD)
by Mark Williams (Author), John Teasdale (Author), Zindel Segal (Author), Jon Kabat-Zinn (Author)
If you’ve ever struggled with depression, take heart. Mindfulness, a simple yet powerful way of paying attention to your most difficult emotions and life experiences, can help you break the cycle of chronic unhappiness once and for all.
In The Mindful Way through Depression, four uniquely qualified experts explain why our usual attempts to “think” our way out of a bad mood or just “snap out of it” lead us deeper into the downward spiral. Through insightful lessons drawn from both Eastern meditative traditions and cognitive therapy, they demonstrate how to... View Details
How to Be Happy (Or at Least Less Sad): A Creative Workbook
by Lee Crutchley (Author), Oliver Burkeman (Foreword)
Author and illustrator Lee Crutchley brings his lively interactive approach to a little-discussed but very common issue: the struggle with depression and anxiety.
Through a series of supportive, surprising, and engaging prompts, HOW TO BE HAPPY (OR AT LEAST LESS SAD) helps readers see things in a new light, and rediscover simple pleasures and everyday joy…or at least feel a little less sad. By turns a workbook, trusted friend, creative outlet, security blanket, and secret diary, the pages of this book will offer solace, distraction, engagement, a fresh perspective, and... View Details
Hardcore Self Help: F**k Depression (Volume 2)
by Robert Duff Ph.D. (Author)
Hardcore Self Help: F**k Depression is the follow up to the best-selling F**K Anxiety. In this book I take the information, tips, and insights that I have gained as a psychologist and translate them into language that doesn’t suck. This is the self-help book for people that don’t usually like self-help books. In Hardcore Self Help: F**K Depression, I talk to you like a friend. That means I speak directly to you without psychobabble. Instead I tell you why your brain is such a troll. I explain why you have literally no energy or motivation. I tell you why people are so terrible at offering... View Details
Cognitive Behavioural Therapy: 7 Ways to Freedom from Anxiety, Depression, and Intrusive Thoughts (Happiness is a trainable, attainable skill!)
by Lawrence Wallace (Author)
A Practical Guide to Mental and Emotional Freedom!
Take action now and download this book for a limited time discount!
Feeling lost about how to effectively treat disturbing intrusive thoughts? You’re not alone!
This book contains brilliant advice from a former sufferer of anxiety, depression, and intrusive thoughts. Inspired by compassion, this book is a gift to fellow casualties of negative thought patterns, destructive behaviors, self-loathers, and those wishing freedom from persistent demons.... View Details
The No-Bullshit Guide to Depression
by Steven Skoczen (Author)
The manual for living with depression that everyone should have been given.
Funny, insightful, and relentlessly honest, The No-Bullshit Guide to Depression sets down the stigma and talks through every aspect of living with depression and building a life you love.
Broken down into bite-sized chapters, this book is packed full with everything you need to know about depression, and 60+ research-backed tools to take it on.
The book doesn't shy away from anything.
It covers day-to-day truths like how food, sleep, and sex get weird and practical insights like how... View Details
Depression: Looking Up from the Stubborn Darkness
by Edward T. Welch (Author)
Where Is God in the Struggle? Looking away from despair towards hope can feel risky. What if God doesn't come through for you? What if you don't feel instantly better? Instead of offering simple platitudes or unrealistic "cure-all" formulas, Edward T. Welch addresses the complex nature of depression with compassion and insight, applying the rich treasures of the gospel, and giving fresh hope to those who struggle. Originally published as Depression: A Stubborn Darkness Light for the Path, this new edition is updated with added content. View Details
Love Yourself Like Your Life Depends On It
by Kamal Ravikant (Author)
In December of 2011, I gave a talk to an audience of scientists, Pentagon officials, politicians, and CEOs on the secret of life and how I'd figured it out the previous summer. Afterwards, people came up individually and told me how much what I'd shared meant to them. This book is based on the truth I spoke about. It's something I learned from within myself, something I believed saved me. And more than that, the way I set about to do it. This is a collection of thoughts on what I learned, what worked, what didn't. Where I succeed and importantly, where I fail daily. The truth is to love... View Details